Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-181-6
- Development stage
- Preclinical
- Lead developer
- Shaman Ventures
- Modality
- Small Molecules
01
Overview
SP-181-6 is a small molecule drug candidate under development by Shaman Ventures for the treatment of autoimmune disorders, specifically rheumatoid arthritis and multiple sclerosis. The compound is part of a pipeline inspired by natural products and ethnobotanical research. Currently in the preclinical stage, SP-181-6 is designed to address the underlying pathology of chronic inflammatory and autoimmune conditions. While its specific molecular target and mechanism of action have not been publicly disclosed, it represents the company's effort to translate traditional medicinal knowledge into modern small molecule therapeutics for complex immune-mediated diseases.
Beyond the preview
Go deeper on SP-181-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-181-6.